To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinoma

To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinoma - To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007488

Enrollment

100

Registered

2012-03-12

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

TACE alone TACE with Sorafenib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.unresectable HCC who are not candidates for surgical resection or local therapy 2.Child pugh scoreA 3.Patients with tumors which are confirmed to the liver and can be treated by TACE(the maximum number of nodule equal to or less than 10). 4.Normal renal function(Cre<1.30, e-GFR>60ml/min) 5.Patients who were fully informed of the study beforehand and signed the informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1.History of malignant tumor 2.Occlusion of the main trunk or first branch of Portal vein 3.T-Bil>3.0mg/dL 4.History of interstitial pneumonitis 5.History of thromboembolism 6.Severe hypertention 7.Leukocytopenia or Thrombocytopenia

Design outcomes

Primary

Measure	Time frame
The frequency of intrahepatic metastasis	—

Secondary

Measure	Time frame
Response rate Safety	—

Countries

Japan

Contacts

Public ContactSatoru Murata

Nippon medical school Department of Radiology

genji@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026